FORT LEE, N.J. — May 5, 2026 — Leads & Copy — Nuvectis Pharma, Inc. (NASDAQ: NVCT) reported its financial results for the first quarter of 2026 and provided an update on recent business progress.
The NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US. Preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy.
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, said that 2026 is off to a good start for Nuvectis as the NXP900 Phase 1b clinical program advances. He noted that the program continues to enroll patients at top sites in the US in both the monotherapy and combination arms of the program.
Bentsur added that at this year’s AACR conference held last month, the company provided preclinical data supporting the use of NXP900 in combination with sotorasib, a RAS inhibitor, in non-small cell lung cancer (NSCLC). According to Bentsur, the combination demonstrated clear synergy both in sotorasib-sensitive and sotorasib-resistant NSCLC models.
Nuvectis’ Chairman and CEO also stated that the company is excited for what’s ahead in 2026 and expects a preliminary data readout from the NXP900 Phase 1b study in the summer. He added that the company continues to operate with financial discipline and remains focused on achieving key clinical development milestones in its NXP900 program in 2026 and beyond.
Nuvectis reported that cash and cash equivalents were $25.1 million as of March 31, 2026, compared to $31.6 million as of December 31, 2025.
The company’s net loss was $6.1 million for the three months ended March 31, 2026, compared to $5.3 million for the three months ended March 31, 2025, an increase of $0.8 million. Non-cash stock-based compensation was $1.9 million for the three months ended March 31, 2026 compared to $1.4 million for the three months ended March 31, 2025.
Research and development expenses were $4.1 million for the three months ended March 31, 2026, compared to $3.7 million for the three months ended March 31, 2025, an increase of $0.4 million. The increase was primarily driven by a $0.4 million increase in manufacturing costs, a $0.3 million increase in employee compensation and benefits, and a $0.2 million increase in clinical trial expenses, partially offset by a $0.5 million reduction in license fees and other professional services.
General and administrative expenses were $2.2 million for the three months ended March 31, 2026, compared to $1.9 million for the three months ended March 31, 2025, an increase of $0.3 million. The increase was primarily driven by a $0.2 million increase in professional and consulting services related to public company expenses and a $0.1 million increase in employee compensation and benefits.
Finance income was $0.2 million for the three months ended March 31, 2026 and 2025.
Nuvectis Pharma, Inc. is focused on developing innovative precision medicines for treating serious conditions of unmet medical need in oncology. The company is developing NXP900, a clinical-stage drug candidate. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study, a drug-drug interaction study in healthy volunteers and the Phase 1b program is ongoing.
Source: Nuvectis Pharma, Inc.
